巴曲酶治疗脑梗死患者纤维蛋白原动态变化情况

Dynamic Changes of Fibrinogen in Patients with Cerebral Infarction Treated with Batroxobin Abstract

目的:探讨巴曲酶治疗脑梗死患者纤维蛋白原变化的影响以及其临床疗效。方法:选取2015.06—2017.08来我院就诊的120例脑梗死患者为研究对象,根据治疗方式的不同,分为观察组和对照组,每组60例。观察组给予巴曲酶静滴,第1d为10U+250m L生理盐水,第3d为5U+250m L生理盐水,第5d为5U+250m L生理盐水,3次注射为一疗程;对照组给予复方丹参注射液静滴,20m L+200m L葡萄糖,1次/d,进行治疗。比较治疗前以及治疗后第2d、第4d、第6d两组患者血浆内纤维蛋白原的水平,以及两组患者的临床疗效。结果:治疗前,两组患者血浆内纤维蛋白原的水平无显著差异,P>0.05;治疗后,两组患者血浆内纤维蛋白原的水平均降低,且观察组血浆内纤维蛋白原的水平显著低于对照组,差异有统计学意义,P<0.05;治疗后,观察组临床总有效率为88.33%(53/60),显著高于对照组的70.00%(42/60),差异有统计学意义,P<0.05。结论:血浆内纤维蛋白原的水平增高是脑梗死患者的危险因素,巴曲酶能显著降低脑梗死患者血浆内纤维蛋白原的水平,且临床疗效显著,在脑梗死患者的治疗中值得推广应用。

Objective： To investigate the effect of batroxobin on changes of fibrinogen in patients with cerebral infarction and its clinical efficacy. Methods： A total of 120 cerebral infarction patients treated in our hospital from 2015.06 to 2017.08 were selected as study subjects. According to the different treatment methods, the patients were divided into observation group and control group, with 60 cases in each group. The observation group was given batroxobin intravenously. The first day was 10 U＋250 m L saline, the third day was 5 U＋250 m L saline, the fifth day was 5 U＋250 m L saline, and three injection was a course of treatment. The control group was given compound Danshen injection intravenous infusion, 20 m L＋200 m L glucose, once a day for treatment. The plasma levels of fibrinogen in the two groups before treatment, and on the 2 nd, 4 th, and 6 th day after treatment were compared, and the clinical efficacy of the two groups was compared. Results： Before treatment, there was no significant difference in plasma fibrinogen levels between the two groups（P〈0.05）. After treatment, plasma fibrinogen levels were decreased in both groups, and plasma fibrinogen level in the observation group was significantly lower than that in the control group, the difference was statistically significant（P〉0.05）. After treatment, the total effective rate in the observation group was 88.33%（53/60）, which was significantly higher than that in the control group of 70.00%（42/60）, P〈0.05. Conclusion： Plasma fibrinogen levels are risk factors for patients with cerebral infarction. Batroxobin can significantly reduce the level of plasma fibrinogen in patients with cerebral infarction, and the clinical efficacy of significant in the treatment of patients with cerebral infarction, thus it is worth promoting application.